Robert E Anders

US Patent:

20210374962, Dec 2, 2021

Filed:

Mar 30, 2021

Appl. No.:

17/218087

Inventors:

- Tucson AZ, US
- Baltimore MD, US
- New York NY, US
Lei TANG - Tucson AZ, US
Xiangxue WANG - Tucson AZ, US
Wenjun ZHANG - Tucson AZ, US
Robert ANDERS - Baltimore MD, US
Luis DIAZ - New York NY, US

International Classification:

G06T 7/00
G16H 10/40
G16H 30/20
G16H 30/40
G16H 50/20
G16H 50/70
G16H 50/50
G16H 20/10
C07K 16/28

Abstract:

A scoring functions is developed and used for identifying patients who might be responsive to a PD-1 axis directed therapy. The scoring functions are obtained by extracting features from multiplex-stained sections, selecting features that correlate with response to the therapy using a feature selection function, and fitting one or more of the selected features to a plurality of candidate scoring functions. A candidate scoring function showing the desired balance between predictive sensitivity and specificity may then selected for incorporation into a scoring system that includes at least an image analysis system.

US Patent:

20180120322, May 3, 2018

Filed:

Nov 10, 2017

Appl. No.:

15/809555

Inventors:

- Baltimore MD, US
Darshil T. Jhaveri - Towson MD, US
Robert Anders - Parkville MD, US

International Classification:

G01N 33/574

Abstract:

We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins. We found that tissue expression of proteins PSMC5, TFRC and PPP1R12A increases during tumor development from normal to pre-malignant to pancreatic tumor. In addition, these proteins were shown to be pancreatic cancer-associated antigens that are recognized by post-vaccination antibodies in the sera of patients that received the vaccine and have demonstrated a favorable disease free survival.

US Patent:

20160327560, Nov 10, 2016

Filed:

May 6, 2016

Appl. No.:

15/148674

Inventors:

- Baltimore MD, US
Darshil T. Jhaveri - Towson MD, US
Robert Anders - Parkville MD, US

International Classification:

G01N 33/574

Abstract:

We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins. We found that tissue expression of proteins PSMC5, TFRC and PPP1R12A increases during tumor development from normal to pre-malignant to pancreatic tumor. In addition, these proteins were shown to be pancreatic cancer-associated antigens that are recognized by post-vaccination antibodies in the sera of patients that received the vaccine and have demonstrated a favorable disease free survival.

US Patent:

20150316554, Nov 5, 2015

Filed:

Dec 2, 2013

Appl. No.:

14/649248

Inventors:

- Baltimore MD, US
Darshil T. Jhaveri - Baltimore MD, US
Robert Anders - Baltimore MD, US

International Classification:

G01N 33/574

Abstract:

We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins. We found that tissue expression of proteins PSMC5, TFRC and PPP1R12A increases during tumor development from normal to pre-malignant to pancreatic tumor. In addition, these proteins were shown to be pancreatic cancer-associated antigens that are recognized by post-vaccination antibodies in the sera of patients that received the vaccine and have demonstrated a favorable disease free survival.